DNLI Share Price | Denali Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Denali Therapeutics, Inc.?

Market Cap: As of Jun 18, Denali Therapeutics, Inc. has a market capitalization of 2,035.32 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Denali Therapeutics reported net sales of 0.00 million and a net profit of -453.94 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 1,229.68 million and total assets of 1,374.18 million.

Q: What does Denali Therapeutics, Inc. do?

Overview:Denali Therapeutics, Inc. is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.Financial Snapshot:Most recent Net Profit: -133 Million (Quarterly Results - Mar 2025)Market cap: USD 2,035.32 Million (Small Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.72Return on Equity: -40.43%Price to Book: 1.81Contact Details:Address: 161 Oyster Point Blvd, SOUTH SAN FRANCISCO CA: 94080-1910Tel: 1 650 8668548Fax: 1 302 6555049Website: https://www.denalitherapeutics.com

Q: Who are in the management team of Denali Therapeutics, Inc.?

As of March 2022, the management team of Denali Therapeutics, Inc. includes the following individuals:- Dr. Vicki Sato, who serves as the Independent Chairman of the Board.- Mr. Ryan Watts, who is the President, Chief Executive Officer, Co-Founder, and Director.- Ms. Nancy Thornberry, who is a Director.- Mr. Douglas Cole, who is an Independent Director.- Ms. Jennifer Cook, who is an Independent Director.- Mr. Jay Flatley, who is an Independent Director.- Mr. Peter Klein, who is an Independent Director.This team is responsible for guiding the company’s strategic direction and operations.

Q: Is Denali Therapeutics, Inc. overvalued or undervalued?

As of 6 November 2024, Denali Therapeutics, Inc. has moved from a valuation grade of risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently overvalued, with a Price to Book Value of 1.90 and negative ratios such as EV to EBIT at -2.57 and EV to EBITDA at -2.61, reflecting ongoing losses and a lack of profitability. In comparison to its peers, Denali's valuation metrics are concerning; for instance, Axsome Therapeutics, Inc. has a P/E ratio of -20.23, while Krystal Biotech, Inc. is considered expensive with a P/E of 25.47. The company's recent performance has also lagged behind broader market indices, with a year-to-date return of -33.17% compared to the S&P 500's gain of 2.44%. Overall, Denali Therapeutics appears to be overvalued given its financial indicators and relative position within its industry.

Q: Is Denali Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Denali Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators including a mildly bullish MACD on the weekly timeframe, but bearish on the monthly. The daily moving averages indicate a mildly bearish trend, while Bollinger Bands show a mildly bullish signal weekly but mildly bearish monthly. The KST is bullish weekly but bearish monthly, and the OBV is mildly bullish monthly. In terms of performance, Denali has underperformed the S&P 500 across multiple periods, with a year-to-date return of -25.32% compared to the S&P's 14.18%, and a one-year return of -46.84% versus 17.82% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.41 M

Shareholding (Dec 2025)

FII

33.97%

Held by 147 FIIs

DII

19.85%

Held by 58 DIIs

Promoter

5.69%

How big is Denali Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Denali Therapeutics, Inc. has a market capitalization of $2,035.32 million, with net sales of $0.00 million and a net profit of -$453.94 million over the latest four quarters. The company reported shareholder's funds of $1,229.68 million and total assets of $1,374.18 million as of Dec'24.

View full answer

What does Denali Therapeutics, Inc. do?

22-Jun-2025

Denali Therapeutics, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, with a market cap of approximately $2.04 billion and a recent net profit of -$133 million. The company has no dividend yield and is currently loss-making.

View full answer

Who are in the management team of Denali Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Denali Therapeutics, Inc.'s management team includes Dr. Vicki Sato (Independent Chairman), Mr. Ryan Watts (President and CEO), and several independent directors: Ms. Nancy Thornberry, Mr. Douglas Cole, Ms. Jennifer Cook, Mr. Jay Flatley, and Mr. Peter Klein. They oversee the company's strategic direction and operations.

View full answer

Is Denali Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 6, 2024, Denali Therapeutics, Inc. is overvalued and has deteriorated to a "does not qualify" rating due to negative financial metrics and a year-to-date return of -33.17%, significantly underperforming compared to its peers and the S&P 500.

View full answer

Is Denali Therapeutics, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Denali Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -25.32% compared to the S&P's 14.18%.

View full answer

Compare Denali Therapeutics, Inc. with Similar Stocks

Arrowhead Pharmaceuticals, Inc.Mirati Therapeutics, Inc.Blueprint Medicines Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3,262 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.91

Return on Equity

-53.85%

Price to Book

3.52

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-129 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

32.25%

6 Months

66.69%

1 Year

52.24%

2 Years

14.53%

3 Years

-1.88%

4 Years

-34.09%

5 Years

-58.84%

Denali Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-178.12%

EBIT to Interest (avg)

-271.59

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.72

Sales to Capital Employed (avg)

0.22

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

1.05%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.52

EV to EBIT

-4.42

EV to EBITDA

-4.51

EV to Capital Employed

27.80

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-628.55%

ROE (Latest)

-53.85%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 66 Schemes (40.48%)

Foreign Institutions

Held by 147 Foreign Institutions (33.97%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -11.93% vs 3.93% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-133.60",
          "val2": "-128.00",
          "chgp": "-4.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-128.50",
          "val2": "-114.80",
          "chgp": "-11.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -21.22% vs -191.18% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-540.50",
          "val2": "-494.10",
          "chgp": "-9.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-512.50",
          "val2": "-422.80",
          "chgp": "-21.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-133.60

-128.00

-4.37%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-128.50

-114.80

-11.93%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -11.93% vs 3.93% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-540.50

-494.10

-9.39%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-512.50

-422.80

-21.22%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -21.22% vs -191.18% in Dec 2024

All Annual Results

Company CV

About Denali Therapeutics, Inc.

Denali Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

Company Coordinates

Company Details

161 Oyster Point Blvd , SOUTH SAN FRANCISCO CA : 94080-1910

Tel: 1 650 8668548

https://www.denalitherapeutics.com

Registrar Details